| Issue Date | Title | Author(s) |
| 2023-06-01 | Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain | Matsuoka, H; Clark, K; Fazekas, B; Oyamada, S; Brown, L; Ishiki, H; Matsuda, Y; Hasuo, H; Ariyoshi, K; Lee, J; Le, BH; Fujiwara, N; Miyaji, T; Agar, MR; Yamaguchi, T; Satomi, E; Iwase, S; Phillips, J; Koyama, A; Currow, DC |
| 2023-06-01 | Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain. | Matsuoka, H; Clark, K; Fazekas, B; Oyamada, S; Brown, L; Ishiki, H; Matsuda, Y; Hasuo, H; Ariyoshi, K; Lee, J; Le, BH; Fujiwara, N; Miyaji, T; Agar, MR; Yamaguchi, T; Satomi, E; Iwase, S; Phillips, J; Koyama, A; Currow, DC |
| 2022-02-07 | Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: a JORTC-PAL16 trial protocol. | Matsuoka, H; Clark, K; Fazekas, B; Oyamada, S; Brown, L; Ishiki, H; Matsuda, Y; Hasuo, H; Ariyoshi, K; Lee, J; Le, B; Allcroft, P; Kochovska, S; Fujiwara, N; Miyaji, T; Lovell, M; Agar, M; Yamaguchi, T; Satomi, E; Iwase, S; Phillips, J; Koyama, A; Currow, DC |
| 2020 | Predictors of duloxetine response in patients with neuropathic cancer pain: a secondary analysis of a randomized controlled trial—JORTC-PAL08 (DIRECT) study | Matsuoka, H; Iwase, S; Miyaji, T; Kawaguchi, T; Ariyoshi, K; Oyamada, S; Satomi, E; Ishiki, H; Hasuo, H; Sakuma, H; Tokoro, A; Matsuda, Y; Tahara, K; Otani, H; Ohtake, Y; Tsukuura, H; Matsumoto, Y; Hasegawa, Y; Kataoka, Y; Otsuka, M; Sakai, K; Nakura, M; Morita, T; Yamaguchi, T; Koyama, A |
